150 related articles for article (PubMed ID: 19154222)
21. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression.
Tulen JH; Volkers AC; van den Broek WW; Bruijn JA
J Clin Psychopharmacol; 2006 Oct; 26(5):542-4. PubMed ID: 16974207
[No Abstract] [Full Text] [Related]
22. Paroxetine treatment of major depressive disorder.
Keller MB
Psychopharmacol Bull; 2003; 37 Suppl 1():42-52. PubMed ID: 14566200
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression.
Politis AM; Papadimitriou GN; Theleritis CG; Psarros C; Soldatos CR
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1227-30. PubMed ID: 18442877
[TBL] [Abstract][Full Text] [Related]
24. High-dose paroxetine treatment for an adolescent with obsessive-compulsive disorder comorbid with Asperger's disorder.
Sasayama D; Sugiyama N; Imai J; Hayashida A; Harada Y; Amano N
Psychiatry Clin Neurosci; 2009 Apr; 63(2):251. PubMed ID: 19335398
[No Abstract] [Full Text] [Related]
25. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients.
Gałecki P; Szemraj J; Bieńkiewicz M; Zboralski K; Gałecka E
Hum Psychopharmacol; 2009 Jun; 24(4):277-86. PubMed ID: 19319921
[TBL] [Abstract][Full Text] [Related]
26. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Montgomery SA; Möller HJ
Int Clin Psychopharmacol; 2009 May; 24(3):111-8. PubMed ID: 19357527
[TBL] [Abstract][Full Text] [Related]
27. Validation of the Depression and Somatic Symptoms Scale by comparison with the Short Form 36 scale among psychiatric outpatients with major depressive disorder.
Hung CI; Wang SJ; Liu CY
Depress Anxiety; 2009; 26(6):583-91. PubMed ID: 19242983
[TBL] [Abstract][Full Text] [Related]
28. Superiority of escitalopram to paroxetine in the treatment of depression.
Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
[TBL] [Abstract][Full Text] [Related]
29. Augmentation strategies in the treatment of major depressive disorder. Clinical considerations with atypical antipsychotic augmentation.
Gitlin MJ
CNS Spectr; 2007 Dec; 12(12 Suppl 22):13-5. PubMed ID: 18389929
[No Abstract] [Full Text] [Related]
30. Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder".
Hashimoto K
J Clin Psychopharmacol; 2009 Aug; 29(4):411-2; author reply 412. PubMed ID: 19593196
[No Abstract] [Full Text] [Related]
31. Olanzapine in the treatment of resistant depression.
Caetano D; Caetano SC
Aust N Z J Psychiatry; 2005; 39(1-2):108-9. PubMed ID: 15660713
[No Abstract] [Full Text] [Related]
32. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
Sato Y; Yasui-Furukori N; Nakagami T; Saito M; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):416-8. PubMed ID: 19166896
[TBL] [Abstract][Full Text] [Related]
33. Treatment of psychotic depression associated with steroid therapy in Churg-Strauss syndrome.
Ismail M; Lyster G
Ir Med J; 2002 Jan; 95(1):18-9. PubMed ID: 11928783
[TBL] [Abstract][Full Text] [Related]
34. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs.
Mohamed S; Leslie DL; Rosenheck RA
J Clin Psychiatry; 2009 Jun; 70(6):906-12. PubMed ID: 19422760
[TBL] [Abstract][Full Text] [Related]
35. Elevation of nortriptyline plasma levels after cotreatment with paroxetine and thioridazine.
Ghaemi SN; Kirkwood CK
J Clin Psychopharmacol; 1998 Aug; 18(4):342-3. PubMed ID: 9690702
[No Abstract] [Full Text] [Related]
36. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.
Maron E; Tammiste A; Kallassalu K; Eller T; Vasar V; Nutt DJ; Metspalu A
Eur Neuropsychopharmacol; 2009 Jun; 19(6):451-6. PubMed ID: 19272758
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
38. Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.
Tanii H; Ichihashi K; Inoue K; Fujita K; Okazaki Y
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1176-8. PubMed ID: 16720068
[TBL] [Abstract][Full Text] [Related]
39. Atypical antipsychotic augmentation in treatment-resistant major depressive disorder.
Delgado A; Ehert M
Conn Med; 2011 Mar; 75(3):153-6. PubMed ID: 21500706
[No Abstract] [Full Text] [Related]
40. [Recurring depression].
Lôo H
Encephale; 2005 Oct; 31 Pt 2():S19-21. PubMed ID: 16673698
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
